Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide in NASH with Fibrosis
NCT03656068Phase 2Completed
- Sponsor
- Pinnacle Clinical Research
- Start
- Dec 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitazoxanide in Nonalcoholic steatohepatitis (NASH), sponsored by Pinnacle Clinical Research. Primary endpoints: Treatment Emergent Adverse Events at 28 weeks and Serious Adverse Events at 28 weeks. Started Dec 2018; status: completed.
02
Drugs
nitazoxanide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03656068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656068.